Explore a recent article that describes the differences between TMB, neoantigen load, PD-L1, CD4, and NK cell proportions according to MET mutation or amplification status.

bit.ly/44C61J4

Oncologist’s dream

Converting an immune desert tumor into an inflamed tumor

Great work on this project!

All-star panel!! Mara Antonoff, MD, FACS Chul Kim #stephenchun

Check an article on patients who completed two years of #pembrolizumab for advanced NSCLC, highlighting high rates of KRAS mutation & PD-L1 expression, and a subset with brain metastases and treated oligoprogression.

Full article: bit.ly/3Qz1FNa

Join us tomorrow, May 8, 2024 (1-2 PM EDT/7-8 PM CET), for an educational webinar on the treatment of thymic tumors, featuring Drs. Mara Antonoff (Mara Antonoff, MD, FACS), Stephen Chun, and Chul Kim (@chulkimMD).

➡️Registration: bit.ly/44fL32J

ITMIG Society

For Thymic Malignancy Awareness Month, the ITMIG Communication Committee, which I have the privilege of chairing, has organized several webinars with no registration fees.

1. An Overview of Thymic Tumors for Patients and Primary Care Teams
Date: May 8, 2024 (1-2 PM EDT / 7-8 PM…

Updated outcomes from phase II Chinese study of lorlatinib 100mg qday in previously treated #ALK NSCLC Clinical Lung Cancer. PFS post crizotinib was 26.3m. PFS after other ALK TKIs was 5.6m. No new safety signals with longer 3y f/u.

clinical-lung-cancer.com/article/S1525-…

#CatsOfTwitter

Webinars for Thymic Malignancy Awareness Month - Chul Kim
Georgetown University Mara Antonoff, MD, FACS Henry Kaminski Claudia Proto Jennifer Marks, MD ITMIG Society
oncodaily.com/58464.html

#AutoimmuneDisease #Cancer #OncoDaily #Oncology #ThymicMalignancyAwarenessMonth #Cancer Awareness

Chul Kim We would like to inform you that your post has been successfully published on @Oncodaily. Thank you for sharing!
oncodaily.com/blog/58464.html

With all of the lung cancer updates this year, be sure to join us in downtown Washington, DC on Saturday, October 19th, 2024 for #DCLung24 for a one-day #CME with all the latest data presented by world class experts! Agenda and registration below:

medstarhealth.org/dclung24

Join us for the webinar on “Clinical Trials for Thymic Tumors,” on May 24th, 2024 at 9:30 am EDT, moderated by Chul Kim! Register at itmig.org/event/clinical…
#ITMIG #thymoma #thymiccarcinoma #TET Hem-Onc Fellows Network ASCO NCICancerTrials Gilead Sciences #ADCs #lcsm

For Thymic Malignancy Awareness Month, the ITMIG Communication Committee, which I have the privilege of chairing, has organized several webinars with no registration fees.

1. An Overview of Thymic Tumors for Patients and Primary Care Teams
Date: May 8, 2024 (1-2 PM EDT / 7-8 PM…

⏰NOW OUT‼️ #ASCO24 Abstract Titles
🔥Lung Cancer - Non-Small Cell Metastatic
☑️ #LBA8500 EVOKE-01 Luis Paz-Ares
☑️#8501 ICARUS-LUNG01 d.planchard
☑️ #LBA8503 CROWN Ben Solomon
☑️#8504 MARIPOSA Enriqueta Felip
☑️ #LBA8505 PALOMA-3 Dr.Natasha Leighl
and others
#LCSM OncoAlert ASCO

To my followers who wonder what MOC is, and why many doctors are tweeting about it. Thread.

1) Maintenance of Certification (MOC) is a redundant requirement thrust on US physicians by a private organization. We resent it.

Thanks to Stephen V Liu, MD, Tina Cascone and IDEOlogy Health for this great conference TLC Conference Misty Dawn Shields Christine Lovly, MD, PhD Brendon Stiles Dr. Estela Rodriguez Narjust Florez, MD, FASCO Rachel E. Sanborn, MD Edgardo S. Santos, M.D., FACP, FASCO Marina Garassino Hossein Borghaei, DO Christian Rolfo Chul Kim Sandip Patel MD…

Great talk on ADCs in lung cancer by our own Joshua Reuss! A class of drugs with excitement and unique challenges (understanding resistance, management and mitigation of AEs, biomarker development). Next generation of ADCs emerging. #TexasLung24

The treatment landscape for KRAS mutant NSCLC is rapidly evolving. Currently approved drugs include sotorasib and adagrasib (for previously treated KRAS G12C NSCLC). Several trials (1st line, combination, newer agents) are underway. Great talk by Melissa L. Johnson. #TexasLung24

In-depth review of BRAF mutant NSCLC by Dr. Marcelo Negrao.

Now we have two FDA approved combination TKI therapies.

Highlighted was ongoing work to understand sequencing of treatment and incorporation of IO in the treatment algorithm.

#TexasLung24